Jennerex Biotherapeutics is reporting a breakthrough that will allow it to deliver its anti-cancer oncolytic viruses via an intravenous route of injection -- as contrasted with the need to directly inject the viruses into a tumor. In a Nature article this week, Jennerex reports it oncolytic viruses injected i.v. were able to migrate from the bloodstream to the tumor site. Eureka!
"The idea has been around for decades, but nobody has been able to show you could deliver [an oncolytic virus] through an IV. If you can achieve IV delivery, it opens up the possibility of treating 10-fold mor tumors," says David Kim, Jennerex CEO. See Xconomy.
There are no approved products using oncolytic viruses or this iv delivery concept but let's give them hand for the latest success. Hopefully, this will work and provide another possible way to go after tumors.
Posted by Bruce Lehr Aug 30th 2011.